John Fenn, who won the 2002 Nobel Prize in Chemistry for his development of electrospray ionization of proteins for mass spectrometry, has been elected as a member of the National Academy of Sciences. He joins a total of 1,992 active members and 341 foreign associates. Fenn is a research professor of chemistry at Virginia Commonwealth University in Richmond.
Dolores Cahill has become center director of the National Center for Human Proteomics at the Royal College of Surgeons in Ireland in Dublin (see article p.1). She has also been appointed assistant professor at the RCSI. Cahill, who holds a PhD from Dublin City University and an undergraduate degree from Trinity College in Dublin, has been leading the protein technologies group at the Max Planck Institute for Molecular Genetics in Berlin since 1998.
J.C. MacRae has become executive vice president and CFO of La Jolla, Calif.-based ActivX Biosciences. He joins the company from Ista Pharmaceuticals of Irvine, Calif., where he was executive vice president, chief operating officer, and chief financial officer. Prior to that, he was vice president, CFO, and managing director of Imagyn Medical of Laguna Niguel, Calif. MacRae holds an MBA from the California State University at Fullerton and a BA from the University of California, Irvine.
Mark Peterson, president of Fidelity Biosciences, a division of Fidelity Investments, and Ben Bronstein, managing director of Zero Stage Capital, have been appointed to the board of directors of US Genomics, based in Woburn, Mass. The company develops technology to detect DNA, RNA, and proteins at the single molecule level.